Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans.
Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
Author(s): Daniel J. Hicklin PhD (auth.), Beverly A. Teicher PhD, Lee M. Ellis MD (eds.)
Series: Cancer Drug Discovery and Development
Edition: 2
Publisher: Humana Press
Year: 2008
Language: English
Pages: 559
Tags: Cancer Research; Oncology; Surgical Oncology; Pharmacology/Toxicology
Front Matter....Pages I-XVIII
Front Matter....Pages 1-1
Vascular Endothelial Growth Factor Family and Its Receptors....Pages 3-26
The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors....Pages 27-47
The Role of Integrins in Tumor Angiogenesis....Pages 49-71
Tumor Endothelial Cell Abnormalities....Pages 73-84
The Extracellular Matrix and VEGF Processing....Pages 85-97
Endothelial Precursor Cells....Pages 99-115
Role of Pericytes in Angiogenesis....Pages 117-132
Newer Vascular Targets....Pages 133-153
Chemokines in Angiogenesis....Pages 155-170
Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis....Pages 171-187
Imaging Angiogenesis....Pages 189-203
Tumor Blood Vessels....Pages 205-224
Lymphatic System in the Pathology of Cancer....Pages 225-241
Front Matter....Pages 243-243
VEGF in the Adult....Pages 245-259
Normalization of Tumor Vasculature and Microenvironment....Pages 261-276
Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man....Pages 277-296
Small-Molecule Vascular Disrupting Agents in Cancer Therapy....Pages 297-310
Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents....Pages 311-321
Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside....Pages 323-330
Regulation of Angiogenesis in Cancer and Its Therapeutic Implications....Pages 331-349
Front Matter....Pages 351-351
Angiogenesis and Angiogenesis Inhibition in Sarcomas....Pages 353-369
Antiangiogenesis Agents in Colorectal Cancer....Pages 371-384
Antiangiogenic Therapy for Primary CNS Tumors....Pages 385-408
Angiogenesis Inhibitors for the Treatment of Lung Cancer....Pages 409-426
Antiangiogenic Therapy of Renal Cell Carcinoma....Pages 427-439
Antiangiogenesis Therapies in Gynecologic Malignancies....Pages 441-456
Antiangiogenic Agents in Myeloid Malignancies....Pages 457-473
Angiogenesis in Malignant and Non-Malignant Pediatric Tumors....Pages 475-486
Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis....Pages 487-508
Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials....Pages 509-524
The Role of Imaging in the Clinical Development of Antiangiogenic Agents....Pages 525-536
Back Matter....Pages 537-559
